A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2016

At a glance

  • Drugs Cenobamate (Primary) ; Antiepileptic drugs
  • Indications Epilepsy
  • Focus Therapeutic Use
  • Sponsors SK Life Science
  • Most Recent Events

    • 21 Sep 2016 Status changed from completed to active, no longer recruiting.
    • 21 Apr 2016 Pooled analysis of seizure-free rates of 2 studies including this trial and another study (see CTP 700203047) were presented at the 68th Annual Meeting of the American Academy of Neurology.
    • 24 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top